‌

US Patent 11878020 Modulators of Rho-associated protein kinase

Patent 11878020 was granted and assigned to Redx Pharma PLC on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Redx Pharma PLC

0

Current Assignee

Redx Pharma PLC

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Liam Byrne0

Clifford D. Jones0

Nicolas E. S. Guisot0

Thomas Pesnot0

Peter Bunyard0

Gary Pitt0

Date of Patent

January 23, 2024

0

Patent Application Number

178966260

Date Filed

August 26, 2022

0

Patent Citations

US Patent 7951820 Triazole compounds useful as protein kinase inhibitors

0

US Patent 11497751 Modulators of Rho-associated protein kinase

0

Patent Primary Examiner

Daniel R Carcanague

0

CPC Code

0

0

0

0

0

0

0

Patent abstract

This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11878020 Modulators of Rho-associated protein kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.